Tumor Biology

, Volume 35, Issue 4, pp 3305–3310 | Cite as

Piperine induces apoptosis of lung cancer A549 cells via p53-dependent mitochondrial signaling pathway

  • Yi Lin
  • Jianping Xu
  • Hehe Liao
  • Lu Li
  • Lei PanEmail author
Research Article


The aim of this study was to evaluate the cytotoxic and apoptotic effects of piperine on human lung cancer A549 cells and to explore its mechanisms. Piperine was found to exert the greatest cytotoxic effect against A549 cells in a dose-dependent manner, whereas it showed no effect on WI38 human lung fibroblasts. This cell growth-inhibitory effect might be attributed to cell DNA damage and cytotoxic effects. Besides, piperine had the ability to cause cell cycle arrest in G2/M phase and to activate caspase-3 and caspase-9 cascades in A549 cells. Furthermore, piperine-induced apoptosis could be blocked by the broad caspase inhibitor z-VAD-fmk in majority. In addition, piperine treatment decreased Bcl-2 protein expression, but increased Bax protein expression in A549 cells, which were positively correlated with an elevated expression of p53 compared to control. Taken together, these results suggested that piperine could induce p53-mediated cell cycle arrest and apoptosis via activation of caspase-3 and caspase-9 cascades, as well as increasing the Bax/Bcl-2 ratio. Thus, piperine could be developed as an effective antitumor agent in the prevention and treatment of lung cancer without toxicity to the host.


Lung cancer Piperine Apoptosis p53 Bax/Bcl-2 Caspase-3 and caspase-9 



This work was supported by the National Natural Science Foundation of China (31100656)

Conflicts of interest



  1. 1.
    Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, et al. Cancer statistics, 2006. CA Cancer J Clin. 2006;56:106–30.PubMedCrossRefGoogle Scholar
  2. 2.
    Hung JY, Hsu YL, Ko YC, Tsai YM, Yang CJ, Huang MS, et al. Didymin, a dietary flavonoid glycoside from citrus fruits, induces Fas-mediated apoptotic pathway in human non-small-cell lung cancer cells in vitro and in vivo. Lung Cancer. 2010;68:366–74.PubMedCrossRefGoogle Scholar
  3. 3.
    Saba NF, Khuri FR. Chemoprevention strategies for patients with lung cancer in the context of screening. Clin Lung Cancer. 2005;7:92–9.PubMedCrossRefGoogle Scholar
  4. 4.
    Ten Bokkel Huinink WW, Bergman B, Chemaissani A, Dornoff W, Drings P, Kellokumpu-Lehtinen PL, et al. Single-agent gemcitabine: an active and better tolerated alternative to standard cisplatin-based chemotherapy in locally advanced or metastatic non-small cell lung cancer. Lung Cancer. 1999;26:85–94.PubMedCrossRefGoogle Scholar
  5. 5.
    Sandler AB, Nemunaitis J, Denham C, von Pawel J, Cormier Y, Gatzemeier U, et al. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 2000;18:122–30.PubMedGoogle Scholar
  6. 6.
    Bonomi P, Kim K, Fairclough D, Cella D, Kugler J, Rowinsky E, et al. Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. J Clin Oncol. 2000;18:623–31.PubMedGoogle Scholar
  7. 7.
    Chou JY, Lai SY, Pan SL, Jow GM, Chern JW, Guh JH. Investigation of anticancer mechanism of thiadiazole-based compound in human non-small cell lung cancer A549 cells. Biochem Pharmacol. 2003;66:115–24.PubMedCrossRefGoogle Scholar
  8. 8.
    Bonomi P. Review of paclitaxel/carboplatin in advanced non-small cell lung cancer. Sem Oncol. 1999;26:55–8.Google Scholar
  9. 9.
    Eisenberg DM, Davis RB, Ettner SL, Appel S, Wilkey S, Van Rompay M, et al. Trends in alternative medicine use in the United States, 1990–1997: results of a follow-up national survey. JAMA. 1998;280:1569–75.PubMedCrossRefGoogle Scholar
  10. 10.
    Risberg T, Lund E, Wist E, Kaasa S, Wilsgaard T. Cancer patients use of nonproven therapy: a 5-year follow-up study. J Clin Oncol. 1998;16:6–12.PubMedGoogle Scholar
  11. 11.
    Chang HC, Hung WC, Huang MS, Hsu HK. Extract from the leaves of Toona sinensis Roemor exerts potent antiproliferative effect on human lung cancer cells. Am J Chin Med. 2002;30:307–14.PubMedCrossRefGoogle Scholar
  12. 12.
    Li YM, Ohno Y, Minatoguchi S, Fukuda K, Ikoma T, Ohno T, et al. Extracts from the roots of Lindera strychifolia induces apoptosis in lung cancer cells and prolongs survival of tumor-bearing mice. Am J Chin Med. 2003;31:857–69.PubMedCrossRefGoogle Scholar
  13. 13.
    Tuntiwechapikul W, Taka T, Songsomboon C, Kaewtunjai N, Imsumran A, Makonkawkeyoon L, et al. Ginger extract inhibits human telomerase reverse transcriptase and c-Myc expression in A549 lung cancer cells. J Med Food. 2010;13:1347–54.PubMedCrossRefGoogle Scholar
  14. 14.
    Reanmongkol W, Janthasoot W, Wattanatorn W, Upakorn PD, Chudapongse P. Effects of piperine on bioenergetics functions of isolated rat liver mitochondria. Biochem Pharmacol. 1988;37:753–7.PubMedCrossRefGoogle Scholar
  15. 15.
    Piyachaturawat P, Kingkaeohoi S, Toskulkao C. Potentiation of carbon tetrachloride hepatotoxicity by piperine. Drug Chem Toxicol. 1995;18:333–44.PubMedCrossRefGoogle Scholar
  16. 16.
    Nakini N, Sabitha K, Viswanathan P, Menon VP. Spices and glycoproteins metabolism in experimental colon cancer in rats. Med Sci Res. 1998;26:781–4.Google Scholar
  17. 17.
    Dhuley JN, Raman PH, Mujumda M, Naik SR. Inhibition of lipid peroxidation by piperine during experimental inflammation in rats. Indian J Exp Biol. 1993;31:443–5.PubMedGoogle Scholar
  18. 18.
    Rashmeet KR, Jaswant S. In vitro and in vivo inhibition of pulmonary cytochrome P450 activities by piperine. J Exp Biol. 1991;29:568–73.Google Scholar
  19. 19.
    Atal CK, Dubey RK, Singh J. Biochemical basis of enhanced drug bioavailability by piperine. Evidence that piperine is a potent inhibitor of drug metabolism. J Pharmacol Exp Ther. 1985;232:258–62.PubMedGoogle Scholar
  20. 20.
    Allameh A, Saxena M, Biswas G, Raj HG, Singh J, Srivastava N. Piperine, a plant alkaloid of the piper species, enhances the bioavailability of aflatoxin B1 in rat tissues. Cancer Lett. 1992;61:195–9.PubMedCrossRefGoogle Scholar
  21. 21.
    Koul IB, Kapil A. Evaluation of the liver protective potential of piperine, an active principle of black and long peppers. Planta Med. 1993;59:413–7.Google Scholar
  22. 22.
    Chu CY, Chang JP, Wang CJ. Modulatory effect of piperine on benzo[a]pyrene cytotoxicity and DNA adduct formation in V-79 lung fibroblast cells. Food Chem Toxicol. 1994;32:373–7.PubMedCrossRefGoogle Scholar
  23. 23.
    Alleme S (1991) Piperine enchanced the bioavailability of the aflatoxin B1 induced in rat tissues. Cancer Lett 195–9.Google Scholar
  24. 24.
    Zhang Y, Wang Q, Wang T, Zhang H, Tian Y, Luo H, et al. Inhibition of human gastric carcinoma cell growth in vitro by a polysaccharide from Aster tataricus. Int J Biol Macromol. 2012;51:509–13.PubMedCrossRefGoogle Scholar
  25. 25.
    Lee TH, Chuang LY, Hung WC. Tamoxifen induces p21Waf1 and p27Kip1 expression in estrogen receptor-negative lung cancer cells. Oncogene. 1999;18:4269–74.PubMedCrossRefGoogle Scholar
  26. 26.
    Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein binding. Anal Biochem. 1976;72:248–54.PubMedCrossRefGoogle Scholar
  27. 27.
    Hung WC, Chuang LY. Sodium butyrate enhances STAT 1 expression in PLC/PRF/5 hepatoma cells and augments their responsiveness to interferon-alpha. Br J Cancer. 1999;80:705–10.PubMedCentralPubMedCrossRefGoogle Scholar
  28. 28.
    Enari M, Sakahira H, Yokoyoma H, Okawa K, Iwamtsu A, Nagata S. A caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor ICAD. Nature. 1998;391:43–50.PubMedCrossRefGoogle Scholar
  29. 29.
    Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, Brown JP, et al. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science. 1998;282:1497–501.PubMedCrossRefGoogle Scholar
  30. 30.
    Karpinich NO, Tafani M, Rothman RJ, Russo MA, Farber JL. The course of etoposide induced apoptosis from damage to DNA and p53 activation to mitochondrial release of cytochrome c. J Biol Chem. 2002;277:16547–52.PubMedCrossRefGoogle Scholar
  31. 31.
    Mercer WE, Shields MT, Amin M, Sauve GJ, Appella E, Romano JW, et al. Negative growth regulation in a glioblastoma tumor cell line that conditionally expresses human wild-type p53. Proc Natl Acad Sci U S A. 1990;87:6166–70.PubMedCentralPubMedCrossRefGoogle Scholar
  32. 32.
    Baker SJ, Markowitz S, Fearon ER, Willson JK, Vogelstein B. Suppression of human colorectal carcinoma cell growth by wild-type p53. Science. 1990;249:912–5.PubMedCrossRefGoogle Scholar
  33. 33.
    Tian Z, Shen J, Moseman AP, Yang Q, Yang J, Xiao P, et al. Dulxanthone A induces cell cycle arrest and apoptosis via up-regulation of p53 through mitochondrial pathway in HepG2 cells. Int J Cancer. 2008;122:31–8.PubMedCrossRefGoogle Scholar
  34. 34.
    Budihardjo I, Oliver H, Lutter M, Luo X, Wang X. Biochemical pathways of caspase activation during apoptosis. Annu Rev Cell Dev Biol. 1999;15:269–90.PubMedCrossRefGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2013

Authors and Affiliations

  • Yi Lin
    • 1
  • Jianping Xu
    • 2
  • Hehe Liao
    • 3
  • Lu Li
    • 1
  • Lei Pan
    • 4
    Email author
  1. 1.Department of Cardiothoracic Surgery306 Hospital of PLABeijingChina
  2. 2.Department of RespirologyXi’an No1 HospitalXi’anChina
  3. 3.Department of Thoracic Surgery and OncologyThe Affiliated Hospital of Xi’an Medical CollegeXi’anChina
  4. 4.Department of Pulmonary DiseasesTangdu Hospital of the Fourth Military Medical UniversityXi’anChina

Personalised recommendations